Drug intelligence / Profile preview

MK-8266

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-8266 is an investigational small molecule drug developed by Merck & Co. for cardiovascular diseases, specifically studied in the context of hypertension. It has undergone Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with mild to moderate hypertension. The mechanism of action has not been explicitly disclosed in public sources; however, it was designed as a novel agent for cardiovascular indications[3].

Targets

GPR119 (Glucose-dependent insulinotropic receptor)

Beyond the preview

Go deeper on MK-8266.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8266.

Explore the full profile